Statement of RDIF and the Gamaleya Institute on Omicron variant of COV…

MOSCOW, Nov. 29, 2021 /PRNewswire/ — The Russian Sputnik V and Sputnik Light vaccines have proven to be highly effective against all variants of SARC-Cov-2 known to date. This has been demonstrated by an article published in Vaccines medical journal and international real-world data from numerous countries:

A recent study in Hungary demonstrated Sputnik V vaccine had the highest (98%) efficacy in preventing COVID-related mortality and 85.7% efficacy against coronavirus infection among five vaccines (Sputnik V, Moderna, Pfizer, AstraZeneca and Sinopharm) used in the country between January-June 2021. Based on this data, the proportion of deaths from COVID in the unvaccinated population was 130 times higher than among those vaccinated with Sputnik V in the same period. According to data from San Marino, Sputnik V is 80% effective against coronavirus infection from 6th to 8th months after administering the second measure, which is much higher than published efficacy of mRNA vaccines of less than 30% after 6 months.

The Sputnik vaccine’s efficacy is based on the heterogeneous boosting approach using two different vectors for two shots, pioneered by the Gamaleya Institute, and a proven adenoviral vector platform, which triggers a broader immune response as compared to mRNA vaccines.

The Gamaleya Institute believes both Sputnik V and Sputnik Light will neutralize the latest Omicron variant and has started the necessary studies.

Nonetheless the Gamaleya Institute, based on existing protocols of closest developing vaccine versions for variants of concern, has already begun developing the new version of Sputnik vaccine alternation to Omicron. In an doubtful case such alteration is needed, the new Sputnik Omicron version can be ready for mass-extent production in 45 days. Several hundred million Sputnik Omicron boosters can be provided to international markets already by Feb 20, 2022 with over 3 billion doses obtainable in 2022.

Kirill Dmitriev, CEO of the Russian Direct Investment Fund, said:

“The Gamaleya Institute believes Sputnik V and Sputnik Light will neutralize Omicron as they have highest efficacy against other mutations. In doubtful case a alteration is needed, we will provide several hundred million of Sputnik Omicron boosters by Feb 20, 2022.”

Logo – https://mma.prnewswire.com/media/1698158/Russian_Direct_Invest_Fund_Logo.jpg

Disclaimer:
This Press Release has not been vetted or endorsed by The Eastern Herald’s editorial staff.

Follow us on: Eastern Herald on Google News

Click: See details

Leave a Reply